PriceTargets.com logo

Indivior - INVVY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.00
  • Forecasted Upside: 128.88%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$21.85 As of 06/9/2023 09:49 PM ET
▼ -0.4045 (-1.82%)

This chart shows the closing price for INVVY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indivior Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INVVY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INVVY

Analyst Price Target is $50.00
▲ +128.88% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Indivior in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 128.88% upside from the last price of $21.85.

This chart shows the closing price for INVVY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Indivior.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/9/2026Craig HallumReiterated RatingBuy ➝ Buy$50.00
10/24/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/25/2022Morgan StanleyInitiated CoverageEqual Weight
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Indivior logo
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Read More

Today's Range

Now: $21.85
Low: $21.64
High: $21.85

50 Day Range

MA: $21.85
Low: $21.85
High: $21.85

52 Week Range

Now: $21.85
Low: $14.76
High: $35.50

Volume

8,100 shs

Average Volume

3,825 shs

Market Capitalization

$3.01 billion

P/E Ratio

20.81

Dividend Yield

N/A

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Indivior?

The following Wall Street sell-side analysts have issued stock ratings on Indivior in the last twelve months: Craig Hallum.
View the latest analyst ratings for INVVY.

What is the current price target for Indivior?

0 Wall Street analysts have set twelve-month price targets for Indivior in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 128.9%. Craig Hallum has the highest price target set, predicting INVVY will reach $50.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $50.00 for Indivior in the next year.
View the latest price targets for INVVY.

What is the current consensus analyst rating for Indivior?

Indivior currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INVVY will outperform the market and that investors should add to their positions of Indivior.
View the latest ratings for INVVY.

What other companies compete with Indivior?

Other companies that are similar to Indivior include Gemini Therapeutics, MorphoSys, Zymeworks, MBX Biosciences and Antibe Therapeutics. Learn More about companies similar to Indivior.

How do I contact Indivior's investor relations team?

Indivior's physical mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The company's listed phone number is 804-379-1090 and its investor relations email address is [email protected]. The official website for Indivior is www.indivior.com. Learn More about contacing Indivior investor relations.